2022 American Transplant Congress
Therapeutic Drug Monitoring of Crushed Posaconazole Delayed Release Tablets in Lung Transplant Patients
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Lung transplant patients are at an increased risk for invasive fungal infections and often require prophylaxis post-transplant, routinely including posaconazole at our institution. These…2022 American Transplant Congress
Induction of Tacrolimus Clearance by Steroids Varies by Cyp3a5 Genotype in Kidney Transplant Recipients: A Drug-Drug-Gene Interaction
*Purpose: Tacrolimus (TAC) is the primary immunosuppressant used in organ transplantation. TAC is a substrate for CYP3A4/5. These enzymes are inhibited or induced by multiple…2022 American Transplant Congress
No Grapefruit Juice Interaction with Tacrolimus LCP in Kidney Transplant Recipients
*Purpose: It is well known that grapefruit juice (GFJ) interacts with many medications through an intestinal CYP3A-mediated interaction that does not involve hepatic CYP3A and…2022 American Transplant Congress
Tacrolimus Exposure Estimation in Stable Kidney Transplant Recipients Using Maximum A Posteriori Bayesian Approach
*Purpose: Tacrolimus exhibits interpatient pharmacokinetic variability that impacts clinical responses and requires routine trough therapeutic drug monitoring. Tacrolimus troughs do not consistently predict area under…2022 American Transplant Congress
Reduced Enterohepatic Recirculation of Mycophenolate and Lower Blood Concentrations Are Associated with the Stool Bacterial Microbiome
*Purpose: Mycophenolate mofetil (MMF) is an important immunosuppressant used after allogeneic hematopoietic cell transplant (HCT). Blood concentrations of mycophenolic acid (MPA) are highly variable and…2021 American Transplant Congress
Managing the Significant Drug-Drug Interaction Between Tacrolimus and Letermovir in Solid Organ Transplant Recipients
NewYork-Presbyterian Hospital, New York, NY
*Purpose: Letermovir does not appear to share cross-resistance with ganciclovir and is not associated with nephrotoxicity or myelosuppressive effects, making it an attractive option for…2021 American Transplant Congress
Tacrolimus Therapeutic Exposure is Not Consistently Predicted by Target Troughs or CYP3A5 Variants in Stable Renal Transplant Recipients
*Purpose: Tacrolimus (TAC) immunosuppression requires therapeutic trough monitoring post-transplant due to notable interpatient pharmacokinetic(PK) variability which may be attributed to CYP3A5 polymorphisms. We investigated the…2021 American Transplant Congress
Belatacept Exposure Not Associated With Rejection. Can Doses be Lowered without Compromising Efficacy?
*Purpose: Phase 1 and 2 belatacept(BELA) pharmacokinetic(PK) studies informed dosing in phase 3 studies. PK data from these studies revealed higher BELA troughs on Day…2021 American Transplant Congress
Evaluation of Conversion to Extended-Release Tacrolimus in Abdominal Organ and Thoracic Transplant Recipients
*Purpose: An established approach for conversion from immediate-release tacrolimus (IR TAC) to extended-release tacrolimus (LCPT) in kidney transplantation exists, but is lacking in other organ…2021 American Transplant Congress
Avoiding Tacrolimus Under- and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial
*Purpose: Bodyweight-based tacrolimus dosing followed by therapeutic drug monitoring is standard clinical care after renal transplantation. However, after transplantation, a meagre 38% of patients is…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 12
- Next Page »